Clik here to view.
SpaceOAR®システムが日本で承認を取得
米マサチューセッツ州ベッドフォード （ビジネスワイヤ） 放射線療法において放射線のリスクから臓器を離し保護するための専有技術である吸収性ハイドロゲルを開発・製造・販売する医療技術企業のAugmenix,...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Bivalirudin for Injection in...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic...
View ArticleClik here to view.
Takeda and Seattle Genetics Announce Lancet Publication of Phase 3 ALCANZA...
CAMBRIDGE, Mass. & OSAKA, Japan & BOTHELL, Wash. Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the randomized...
View ArticleClik here to view.
ウォーターズがnanoEase M/Zカラムを発売
マサチューセッツ州ミルフォード （ビジネスワイヤ） — ウォーターズコーポレーション（NYSE:WAT）は、ナノフローおよびマイクロフローのUPLC/MS向けの次世代カラムを発売しました。Waters nanoEase M/Zカラムは、簡単に取り付けができ、接続によるばらつきを抑え、優れたクロマトグラフィー性能を発揮します。 nanoEase...
View ArticleClik here to view.
口服IDHIFA® (enasidenib) 1期试验的更新数据显示IDH2突变的复发或难治AML患者的完全缓解率和缓解持续时间
芝加哥 (美国商业资讯) — Celgene Corporation (NASDAQ:CELG)与Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)今天发布了进行中的1期剂量递增和扩展研究的有效性及安全性新数据，该研究评估口服研究药物IDHIFA® (enasidenib)用于异柠檬酸脱氢酶-2 (IDH2)突变的复发或难治急性粒细胞性白血病(R/R...
View ArticleClik here to view.
PeptiDream Announces Licensing of Peptide Discovery Platform System (PDPS)...
TOKYO PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a Technology License Agreement with Osaka-based Shionogi...
View ArticleClik here to view.
PSE凭借烯烃技术荣获“烃加工奖”
伦敦 (美国商业资讯)–先进工艺建模公司Process Systems Enterprise (PSE)成为新设立的“《烃加工》最佳自动化与建模奖”(Hydrocarbon Processing Best Automation &...
View ArticleClik here to view.
Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in...
SOUTH SAN FRANCISCO, Calif. Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of the dose-escalation stage of a phase 1b trial of cabozantinib in combination with atezolizumab (TECENTRIQ®)...
View ArticleClik here to view.
Numerate and Takeda Enter Agreement to Generate Novel Clinical Candidates...
SAN BRUNO, Calif. Numerate, Inc., a computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery, announced the formation of a...
View ArticleClik here to view.
IDHIFA®（enasidenib）経口薬の第1相試験から得た最新データは、IDH2変異を持つ再発性／難治性AML患者における完全奏功率および奏功期間を示す
シカゴ （ビジネスワイヤ） — セルジーン・コーポレーション（NASDAQ:CELG）とアジオス・ファーマシューティカルズ（NASDAQ:AGIO）は本日、進行中の第1相用量漸増／拡大試験から得た有効性／安全性データを発表しました。本試験は、イソクエン酸デヒドロゲナーゼ2（IDH2）変異持つ再発性／難治性急性骨髄性白血病（R/R...
View ArticleClik here to view.
PSEがオレフィン向け技術で炭化水素処理賞を獲得
ロンドン （ビジネスワイヤ） — 高度プロセスモデリング企業のプロセス・システムズ・エンタープライズ（PSE）は、新設された炭化水素処理自動化＆モデリング最優秀賞（Hydrocarbon Processing Best Automation & Modeling...
View ArticleClik here to view.
Phase 1 Clinical Study Results of REMD Biotherapeutics’ Lead Product...
CAMARILLO, Calif. REMD Biotherapeutics, Inc. (“REMD Bio”), together with its subsidiary, Beijing-based Cosci-REMD Biotherapeutics (“Cosci-REMD Bio”), today announced data from a Phase 1 clinical...
View ArticleClik here to view.
Starpharma Sells Agrochemicals Business to Agrium for $35M
MELBOURNE, Australia Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that it has completed a transaction to sell its agrochemicals and Priostar® business (Starpharma Agrochemicals)...
View ArticleClik here to view.
Kieran Murphy受命接替John Flannery担任GE医疗集团首席执行官
波士顿 (美国商业资讯)–通用电气(GE)董事长兼首席执行官Jeff Immelt今日宣布，任命Kieran Murphy担任GE医疗集团总裁兼首席执行官，立即生效。Murphy目前担任GE医疗生命科学业务的总裁兼首席执行官，他将接替John Flannery，后者已被任命为通用电气公司继任首席执行官兼董事长。...
View ArticleClik here to view.
Clik here to view.
Celltrion Healthcare showcases data supporting the efficacy and safety of...
INCHEON, South Korea New data presented at the International Conference on Malignant Lymphoma (ICML) and the European League Against Rheumatism (EULAR) congress 2017 demonstrate that CT-P10 is...
View ArticleClik here to view.
ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of...
SAN DIEGO ACEA Biosciences today announced the completion of its Phase 1 clinical study of AC0058, a novel irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor, which is in development for the...
View ArticleClik here to view.
Pimodivir Alone or in Combination with Oseltamivir Demonstrated a Significant...
SHANGHAI Janssen Pharmaceuticals, Inc. (Janssen) today announced results from the Phase 2b Topaz Trial which demonstrated that treatment with pimodivir (JNJ-63623872) significantly decreased viral...
View ArticleClik here to view.
Humacyte® Selected as 2017 Technology Pioneer by World Economic Forum
RESEARCH TRIANGLE PARK, N.C. Humacyte, an innovator in biotechnology and regenerative medicine, was selected among hundreds of candidates as one of the World Economic Forum’s 30 “Technology...
View ArticleClik here to view.
Intensity Therapeutics Issued New Patents for Technology Platform
WESTPORT, Conn. Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States...
View Article